Regeneron Pharmaceuticals Faces Securities Fraud Class Action

Investigation into Misleading Marketing Practices

San Francisco, CA / ACCESS Newswire / January 28, 2025 / Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is currently under fire as they face a securities fraud class action following a significant drop in their stock value on October 31, 2024. The plummeting of shares by $84.59 resulted in a loss of approximately $9 billion in market value for the company. As a response, Hagens Berman has initiated an investigation to determine whether Regeneron may have provided misleading information to investors regarding their marketing and reimbursement practices related to their EYLEA® product.

What is EYLEA®?

EYLEA® is an injection developed by Regeneron Pharmaceuticals to treat age-related macular degeneration by inhibiting anti-vascular endothelial growth factor (“anti-VEGF”). This condition affects the macula, which is the central part of the retina responsible for our central vision. By inhibiting anti-VEGF, EYLEA® aims to slow down the progression of the disease and preserve vision in patients.

Investors who have purchased shares of Regeneron Pharmaceuticals and experienced substantial financial losses are encouraged to submit their losses for investigation. The implications of this securities fraud class action could have far-reaching consequences for the company and its stakeholders.

How This Affects Me

If you are an investor who has purchased Regeneron Pharmaceuticals shares, you may be impacted by the outcome of this securities fraud class action. Depending on the findings of the investigation, there may be potential legal recourse available to recover any losses incurred as a result of misleading information provided by the company.

Global Impact

The allegations of securities fraud against Regeneron Pharmaceuticals could have broader implications for the pharmaceutical industry as a whole. Transparency and honesty in marketing practices are crucial for maintaining investor confidence and ensuring the integrity of the financial markets. If proven true, this case may lead to increased scrutiny of pharmaceutical companies and their communication with investors.

Conclusion

As the investigation into Regeneron Pharmaceuticals’ marketing and reimbursement practices unfolds, the potential consequences of this securities fraud class action are becoming increasingly apparent. Investors are urged to stay informed about the developments in this case and consider their options moving forward. Transparency and accountability are essential for the long-term success and credibility of companies in the pharmaceutical industry.